Precigen Inc PGEN:NASDAQ

Last Price$1.81NASDAQ Previous Close - Last Trade as of 4:00PM ET 2/08/23

Today's Change-0.06(3.21%)
Bid (Size)$1.79 (2)
Ask (Size)$1.88 (10)
Day Low / High$1.78 - 1.89
Volume1.9 M
 

View Biotechnology IndustryPeer Comparison as of 02/08/2023

 

Precigen Inc ( NASDAQ )

Price: $1.81
Change: -0.06 (3.21%)
Volume: 1.9 M
4:00PM ET 2/08/2023
 
 

Kezar Life Sciences Inc ( NASDAQ )

Price: $6.51
Change: -0.27 (3.98%)
Volume: 343.7 K
4:00PM ET 2/08/2023
 
 

Sorrento Therapeutics Inc ( NASDAQ )

Price: $0.98
Change: -0.07 (6.33%)
Volume: 6.5 M
4:00PM ET 2/08/2023
 
 

NGM Biopharmaceuticals Inc ( NASDAQ )

Price: $5.10
Change: -0.29 (5.38%)
Volume: 200.6 K
4:00PM ET 2/08/2023
 
 

Bionano Genomics Inc ( NASDAQ )

Price: $1.65
Change: -0.07 (4.07%)
Volume: 6.0 M
4:00PM ET 2/08/2023
 

Read more news Recent News

Insider Buy: Precigen
4:08PM ET 1/31/2023 MT Newswires

Randal J Kirk, 10% Owner, Director, on January 27, 2023, executed a purchase for 11,428,571 shares in Precigen (PGEN) for $19,999,999. Following the Form 4...

--Cantor Fitzgerald Adjusts Price Target on Precigen to $10 From $7, Maintains Overweight Rating
10:34AM ET 1/30/2023 MT Newswires

(MT Newswires covers equity, commodity and economic research from major banks and research firms in North America, Asia and Europe. Research providers may...

Precigen Closes $75 Million Common Stock Offering
4:27AM ET 1/30/2023 MT Newswires

Precigen (PGEN) said Friday it has closed its public offering of common stock, raising about $75 million in gross proceeds. The company said it has sold...

Sector Update: Health Care Stocks Largely Sit Out Late Market Rebound
4:09PM ET 1/25/2023 MT Newswires

Health care stocks were ending little changed this afternoon, with the NYSE Health Care Index climbing 0.1% and the Health Care Select Sector SPDR Fund...

View all Commentary and Analysis

Precigen: Will Financing Issues Forever Cloud The Promise?
7:34AM ET 1/31/2023 Seeking Alpha

Miller Opportunity Equity 3Q22 Quarterly Investment Review
9:45PM ET 10/26/2022 Seeking Alpha

Circling Back On Precigen
5:24PM ET 8/23/2022 Seeking Alpha

Precigen, Inc. (PGEN) CEO Helen Sabzevari on Q2 2022 Results - Earnings Call Transcript
8:21PM ET 8/08/2022 Seeking Alpha

Company Profile

Business DescriptionPrecigen, Inc. is a biotechnology company, which engages in the research and development of synthetic biology technologies. It operates through the following segments: Biopharmaceuticals, Exemplar, and Trans Ova. The Biopharmaceuticals segment is involved in advancing the next generation of gene and cell therapies using precision technology to target urgent and intractable diseases in immuno-oncology, autoimmune disorders, and infectious diseases. It also engages in pioneering a proprietary class of microbe-based biopharmaceuticals that enable expression and local delivery of disease-modifying therapeutics. The Exemplar segment is focused on developing research models and services for healthcare research applications. The Trans Ova segment provides bovine reproductive technologies. The company was founded by Thomas David Reed in 1998 and is headquartered in Germantown, MD. View company web site for more details
Address20358 Seneca Meadows Parkway
Germantown, Maryland 20876
Phone+1.301.556.9900
Number of Employees882
Recent SEC Filing01/31/20234
President, Chief Executive Officer & DirectorHelen Sabzevari
Chief Operating OfficerRutul R. Shah
Chief Financial OfficerHarry Thomasian
Chief Science OfficerThomas David Reed

Company Highlights

Price Open$1.89
Previous Close$1.87
52 Week Range$1.12 - 2.90
Market Capitalization$454.3 M
Shares Outstanding251.0 M
SectorHealth Technology
IndustryBiotechnology
Next Earnings Announcement03/07/2023

Options Summary

Call Open Interest (1d)*
Put Open Interest (1d)*
Call Volume (1d)*
Put Volume (1d)*
Put Call Open Interest Ratio (1d)*
Put Call Volume Ratio (1d)*
* Data delayed by up to 15 minutes

View all fundamentalsFundamentals

Price / Earnings15.25
Earnings per Share-$0.34
Beta vs. S&P 500N/A
Revenue$160.6 M
Net Profit Margin-102.78%
Return on Equity-82.23%

Analyst Ratings as of 11/17/2022

Buy
4
Overweight
0
Hold
0
Underweight
0
Sell
0
Consensus RecommendationConsensus Icon
Powered by Factset